Bio-Rad Laboratories (NYS: BIO) reported earnings on May 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Bio-Rad Laboratories met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share contracted.
Gross margins grew, operating margins dropped, net margins dropped.
Bio-Rad Laboratories tallied revenue of $486.3 million. The three analysts polled by S&P Capital IQ hoped for revenue of $492.4 million on the same basis. GAAP reported sales were 0.2% higher than the prior-year quarter's $485.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.09. The three earnings estimates compiled by S&P Capital IQ averaged $1.02 per share. GAAP EPS of $1.09 for Q1 were 6.0% lower than the prior-year quarter's $1.16 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 57.3%, 10 basis points better than the prior-year quarter. Operating margin was 11.2%, 260 basis points worse than the prior-year quarter. Net margin was 6.4%, 40 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $522.3 million. On the bottom line, the average EPS estimate is $1.16.
Next year's average estimate for revenue is $2.15 billion. The average EPS estimate is $5.36.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 182 members out of 191 rating the stock outperform, and nine members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 51 give Bio-Rad Laboratories a green thumbs-up, and none give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Rad Laboratories is outperform, with an average price target of $111.50.
Add Bio-Rad Laboratories to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.